| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | INSIG2 |
| Uniprot No | Q9Y5U4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-225aa |
| 氨基酸序列 | MAEGETESPG PKKCGPYISS VTSQSVNLMI RGVVLFFIGV FLALVLNLLQ IQRNVTLFPP DVIASIFSSA WWVPPCCGTA SAVIGLLYPC IDRHLGEPHK FKREWSSVMR CVAVFVGINH ASAKVDFDNN IQLSLTLAAL SIGLWWTFDR SRSGFGLGVG IAFLATVVTQ LLVYNGVYQY TSPDFLYVRS WLPCIFFAGG ITMGNIGRQL AMYECKVIAE KSHQE |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于INSIG2重组蛋白的3篇代表性文献摘要(文献标题及内容为模拟示例，仅供参考)：
---
1. **文献名称**：*Regulation of SREBP processing by INSIG2 through recombinant expression analysis*
**作者**：Gong Y., et al.
**摘要**：本研究通过重组表达人源INSIG2蛋白，验证其与内质网定位的SCAP蛋白相互作用的能力。实验表明，INSIG2重组蛋白可竞争性结合SCAP，抑制SREBP的激活，从而调控胆固醇合成通路。
---
2. **文献名称**：*Structural insights into the transmembrane domain of INSIG2 using recombinant mutants*
**作者**：Yang T., et al.
**摘要**：通过构建INSIG2重组蛋白的跨膜结构域突变体，结合冷冻电镜技术解析其三维结构。研究发现，特定疏水残基对INSIG2与固醇分子的结合及后续信号传导至关重要。
---
3. **文献名称**：*Recombinant INSIG2 suppresses hepatocellular carcinoma progression via Hedgehog pathway modulation*
**作者**：Chen X., et al.
**摘要**：利用重组INSIG2蛋白进行体外肝癌细胞干预实验，证实其过表达可通过下调Hedgehog信号通路抑制肿瘤细胞增殖和迁移，提示INSIG2作为潜在治疗靶点。
---
**提示**：若需获取真实文献，建议在PubMed或Web of Science中搜索关键词“INSIG2 recombinant protein”或“INSIG2 expression”，并筛选涉及蛋白表达、结构功能或疾病机制的研究。部分研究可能聚焦于代谢疾病、癌症或病毒感染领域。
INSIG2 (insulin-induced gene 2) is a protein encoded by the INSIG2 gene, which plays a critical role in lipid metabolism and cholesterol homeostasis. It is part of the insulin-induced gene family, alongside INSIG1. and functions as a key regulator of sterol regulatory element-binding protein (SREBP) pathways. INSIG2 is primarily localized in the endoplasmic reticulum (ER) membrane, where it interacts with SREBP cleavage-activating protein (SCAP) and hydroxymethylglutaryl-CoA reductase (HMGCR), central components of cholesterol and fatty acid biosynthesis.
The protein acts as a sensor of cellular cholesterol levels. Under high sterol conditions, INSIG2 binds to SCAP, retaining the SCAP-SREBP complex in the ER and preventing SREBP translocation to the Golgi apparatus. This inhibits the proteolytic activation of SREBP transcription factors, thereby downregulating genes involved in cholesterol and lipid synthesis. Additionally, INSIG2 facilitates the sterol-accelerated degradation of HMGCR, a rate-limiting enzyme in cholesterol biosynthesis.
Recombinant INSIG2 protein is produced using expression systems (e.g., E. coli or mammalian cells) for in vitro studies. Its recombinant form enables researchers to investigate molecular mechanisms of lipid regulation, drug interactions, and disease associations. Dysregulation of INSIG2 has been linked to metabolic disorders, including obesity, type 2 diabetes, and atherosclerosis. Studies also suggest its involvement in cancer progression, as altered cholesterol metabolism is a hallmark of tumorigenesis.
Research applications include protein-protein interaction assays, structural studies, and screening for lipid-lowering therapeutics. Recombinant INSIG2 provides a tool to dissect SREBP pathway dynamics and explore therapeutic strategies targeting metabolic syndromes or cancers driven by lipid signaling abnormalities.
×
